Despite a challenging quarter with decreased revenues, Laboratorios Farmaceuticos Rovi SA (STU:41L) focuses on strategic expansions and product approvals to drive future growth.

In a report released on September 10, Pablo de Renteria from Kepler Capital maintained a Buy rating on Laboratorios Farmaceuticos Rovi (0ILL – Research Report), with a price target of €104.00.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Las acciones de Rovi cotizan y se negocian en la bolsa de valores Madrid. ¿Cuál es el símbolo bursátil de Rovi? El símbolo bursátil de Rovi es “ROVI”. ¿Paga Rovi dividendos?

Spain stocks were higher after the close on Tuesday, as gains in the Consumer Services, Chemical, Petroleum & Plastic and ...

¿Te imaginas trabajar en una empresa líder del sector farmacéutico? Trabajar en Rovi no solo es una oportunidad profesional, ...

Norbel Inversiones, vehículo inversor de la familia López-Belmonte, fundadores y accionistas mayoritarios de Laboratorios Rovi, ha elevado al 58,186% su participación en Rovi, lo que supone ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Todos los desfibriladores se ubicarán en una vitrina cardíaca instalada en puntos estratégicos de las farmacias y con la máxima accesibilidad y visibilidad. Fotos del Ayuntamiento La alcaldesa de Alca ...

Spain equities were higher at the close on Tuesday, as gains in the Madrid Consumer Services, Madrid Petrol and Power and ...